Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 1 | Biological Procedures Online

Fig. 1

From: Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance

Fig. 1

Flowchart of patient enrollment and study design. EGFR-TKI resistant NSCLC patients who received ICI plus chemotherapy were enrolled. The whole cohort include 60 patients and information of clinical characteristics and outcomes were collected. Among them, 24 patients were considered as PBMC cohort whose PBMC samples at baseline and 2 cycles of ICI plus chemotherapy were collected. All PBMC samples were detected through full spectrum flow cytometry and a 23-color-antibody panel was designed to profile the immune cells in peripheral blood. Abbreviations: NLR, neutrophil to lymphocyte ratio. PLR, platelet-to-lymphocyte ratio. Pre-tx, pre-treatment. On-tx, on treatment. PBMC, peripheral blood mononuclear cell. ICPs, immune checkpoint proteins. MFI, mean fluorescence intensity. EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor. NSCLC, non-small cell lung cancer. ICI, immune checkpoint inhibitor. ORR, objective response rate. CB, clinical benefits. PFS, progression-free survival

Back to article page